Narsimha Reddy Penthala

US Patent:

8304421, Nov 6, 2012

Filed:

Sep 30, 2009

Appl. No.:

12/571425

Inventors:

Peter A. Crooks - Nicholasville KY, US
Thirupathi R. Yerramreddy - Lexington KY, US
Narsimha R. Penthala - Lexington KY, US
Michael L. Freeman - Franklin TN, US
Sekhar R. Konjeti - Nashville TN, US

Assignee:

Vanderbilt University - Nashville TN
University of Kentucky Research Foundation - Lexington KY

International Classification:

A61K 31/515
A61K 31/415
C07D 401/06
C07D 233/02

US Classification:

514270, 514385, 544300, 5483114

Abstract:

Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent.

US Patent:

20230127633, Apr 27, 2023

Filed:

Oct 11, 2022

Appl. No.:

17/964003

Inventors:

- Washington DC, US
- Little Rock AR, US
Kottayil I. Varughese - Little Rock AR, US
Shraddha Thakkar - Little Rock AR, US
Yao Dai - Little Rock TN, US
Peter Crooks - Little Rock AR, US
Narsimha Reddy Penthala - Little Rock AR, US

International Classification:

C07D 231/12
C07D 231/38
C07D 231/14
A61K 31/4164
A61K 31/415
C07D 233/28
C07D 233/22

Abstract:

Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.

US Patent:

20230100940, Mar 30, 2023

Filed:

Jun 14, 2022

Appl. No.:

17/840436

Inventors:

- Radnor PA, US
- Little Rock AR, US
Peter Anthony Crooks - Little Rock AR, US
Narsimha Reddy Penthala - Little Rock AR, US
Zaineb Albayati - Little Rock AR, US

Assignee:

MITOCHON PHARMACEUTICALS, INC. - Radnor PA
BIOVENTURES, LLC - Little Rock AR

International Classification:

A61K 31/5375
A61K 31/4453
A61K 31/495
A61K 31/06
A61K 31/4409
C07C 323/58
C07F 9/12
A61K 31/40
A61K 31/265
A61K 31/27
C07C 205/37
A61K 31/223
A61K 31/4406
A61K 31/661
C07F 9/09
A61K 31/221
C07C 271/44
C07C 219/04
C07C 271/52
C07C 229/26
A61K 31/44
A61K 31/4402
C07C 229/08
C07C 229/22

Abstract:

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

US Patent:

20200199256, Jun 25, 2020

Filed:

Jul 30, 2018

Appl. No.:

16/634703

Inventors:

- Little Rock AR, US
Jamie HESTEKIN - Fayetteville AR, US
Peter CROOKS - Little Rock AR, US
Narsimha Reddy PENTHALA - Little Rock AR, US
Shobanbabu BOMMAGANI - Little Rock AR, US
Soma Shekar DACHAVARAM - Little Rock AR, US

International Classification:

C08B 15/04
B65D 65/46
B65D 81/18

Abstract:

In one aspect, TEMPO-cellulose structures and method of making the same are described herein. Briefly, a method of synthesizing TEMPO-cellulose comprises disposing cellulose in an aqueous medium, disposing first and second oxidizing agents in the aqueous medium and oxidizing hydroxyl groups of the cellulose via the first and second oxidizing agents in the presence of a 2,2,6,6-tetramethylpiperidine 1-oxyl radical (TEMPO) catalyst.

US Patent:

20200123112, Apr 23, 2020

Filed:

Dec 19, 2019

Appl. No.:

16/721103

Inventors:

- Washington DC, US
Kottayil I. Varughese - Little Rock AR, US
Shraddha Thakkar - Little Rock AR, US
Yao Dai - Little Rock TN, US
Peter Crooks - Little Rock AR, US
Narsimha Reddy Penthala - Little Rock AR, US

International Classification:

C07D 231/12
A61K 31/415
A61K 31/4164
C07D 231/14
C07D 231/38
C07D 233/22
C07D 233/28

Abstract:

Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.

US Patent:

20200093831, Mar 26, 2020

Filed:

Nov 26, 2019

Appl. No.:

16/695653

Inventors:

- Radnor PA, US
- Little Rock AR, US
Peter Anthony Crooks - Little Rock AR, US
Narsimha Reddy Penthala - Little Rock AR, US
Zaineb Albayati - Little Rock AR, US

Assignee:

MITOCHON PHARMACEUTICALS, INC. - Radnor PA
BIOVENTURES, LLC - Little Rock AR

International Classification:

A61K 31/5375
C07C 229/22
C07C 229/08
A61K 31/4402
A61K 31/44
C07C 229/26
C07C 271/52
C07C 219/04
C07C 271/44
A61K 31/221
C07F 9/09
A61K 31/661
A61K 31/4406
A61K 31/223
C07C 205/37
A61K 31/27
A61K 31/265
A61K 31/40
C07F 9/12
C07C 323/58
A61K 31/4409
A61K 31/06
A61K 31/495
A61K 31/4453

Abstract:

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

US Patent:

20180305318, Oct 25, 2018

Filed:

Oct 28, 2016

Appl. No.:

15/771085

Inventors:

- Little Rock AR, US
- Washington DC, US
Kottayil I. Varughese - Little Rock AR, US
Shraddha Thakkar - Little Rock AR, US
Yao Dai - Little Rock AR, US
Peter Crooks - Little Rock AR, US
Narsimha Reddy Penthala - Little Rock AR, US

International Classification:

C07D 231/12

Abstract:

Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.

US Patent:

20180237458, Aug 23, 2018

Filed:

Apr 19, 2018

Appl. No.:

15/957524

Inventors:

- Little Rock AR, US
- Denver CO, US
Narsimha Reddy Penthala - Little Rock AR, US
Craig Jordan - Denver CO, US
Shobanbabu Bommagani - Little Rock AR, US
Jessica Ponder - Denver CO, US

International Classification:

C07D 519/00
C07F 7/18

Abstract:

The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML).